These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 34708568)

  • 1. Did our pharmacological strategy for COVID-19 fail?
    Martin JH; Baddeley M; Head R
    Pharmacol Res Perspect; 2021 Dec; 9(6):e00866. PubMed ID: 34708568
    [No Abstract]   [Full Text] [Related]  

  • 2. Renin-angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis.
    Lee MMY; Docherty KF; Sattar N; Mehta N; Kalra A; Nowacki AS; Solomon SD; Vaduganathan M; Petrie MC; Jhund PS; McMurray JJV
    Eur Heart J Cardiovasc Pharmacother; 2022 Feb; 8(2):165-178. PubMed ID: 33337478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and COVID-19: Demonstrating the Actionability of Real-World Evidence.
    Hennessy S; Cohen JB
    Am J Hypertens; 2021 Apr; 34(4):327-329. PubMed ID: 33156920
    [No Abstract]   [Full Text] [Related]  

  • 4. From Foe to Friend in COVID-19: Renin-Angiotensin System Inhibitors.
    Kidde J; Sahebkar A
    J Infect Dis; 2021 Jan; 223(1):174-175. PubMed ID: 33010158
    [No Abstract]   [Full Text] [Related]  

  • 5. Impact of renin-angiotensin-aldosterone system inhibitors on COVID-19.
    Matsuzawa Y; Kimura K; Ogawa H; Tamura K
    Hypertens Res; 2022 Jul; 45(7):1147-1153. PubMed ID: 35581498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Role of age, comorbidity and renin- angiotensin-aldosterone system in COVID-19. Effects of ACE inhibitors and angiotensin receptor blockers].
    Mareev YV; Mareev VY
    Kardiologiia; 2020 Apr; 60(4):4-9. PubMed ID: 32394850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update Alert 6: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.
    Mackey K; Kansagara D; Vela K
    Ann Intern Med; 2021 Jan; 174(1):W17. PubMed ID: 33253036
    [No Abstract]   [Full Text] [Related]  

  • 8. COVID-19 and the Renin-Angiotensin-Aldosterone System.
    Naik GOA
    Clin Infect Dis; 2021 Mar; 72(6):1105-1107. PubMed ID: 32561913
    [No Abstract]   [Full Text] [Related]  

  • 9. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
    Shukla AK; Banerjee M
    High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):129-139. PubMed ID: 33635533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers benefits outweigh the risks in COVID-19 hypertensive patients.
    Ateya AM; Sabri NA
    J Med Virol; 2021 Apr; 93(4):1873-1874. PubMed ID: 33200431
    [No Abstract]   [Full Text] [Related]  

  • 11. SARS-CoV-2 effects on the renin-angiotensin-aldosterone system, therapeutic implications.
    Ye Q; Lai EY; Luft FC; Persson PB; Mao J
    Acta Physiol (Oxf); 2021 Apr; 231(4):e13608. PubMed ID: 33350096
    [No Abstract]   [Full Text] [Related]  

  • 12. Renin-angiotensin-aldosterone system peptide profiles in patients with COVID-19.
    Kutz A; Conen A; Gregoriano C; Haubitz S; Koch D; Domenig O; Bernasconi L; Mueller B; Schuetz P
    Eur J Endocrinol; 2021 Apr; 184(4):543-552. PubMed ID: 33539316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renin-Angiotensin-Aldosterone System Inhibitors and Outcome in Patients With SARS-CoV-2 Pneumonia: A Case Series Study.
    Conversano A; Melillo F; Napolano A; Fominskiy E; Spessot M; Ciceri F; Agricola E
    Hypertension; 2020 Aug; 76(2):e10-e12. PubMed ID: 32383626
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparative Impacts of ACE (Angiotensin-Converting Enzyme) Inhibitors Versus Angiotensin II Receptor Blockers on the Risk of COVID-19 Mortality.
    Zhou F; Liu YM; Xie J; Li H; Lei F; Yang H; Qin JJ; Cai J; Zhang XJ; Wu B; Xia M; Xiang D; Yang C; Ma X; Xu Q; Lu Z; Lu H; Xia X; Wang D; Liao X; Peng G; Yang J; Huang X; Zhang BH; Yuan Y; Wei X; Liu PP; Wang Y; Zhang P; She ZG; Xia J; Li H
    Hypertension; 2020 Aug; 76(2):e15-e17. PubMed ID: 32493070
    [No Abstract]   [Full Text] [Related]  

  • 15. Assessment of ACE inhibitors/angiotensin receptor blockers in COVID-19 patients.
    Sriram K; Insel PA
    Am J Physiol Lung Cell Mol Physiol; 2020 Jul; 319(1):L37-L38. PubMed ID: 33496632
    [No Abstract]   [Full Text] [Related]  

  • 16. A Meta-analysis of the Relationship Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19.
    Usman MS; Siddiqi TJ; Khan MS; Ahmed A; Ali SS; Michos ED; Hall ME; Krasuski RA; Greene SJ; Butler J; Alkhouli M
    Am J Cardiol; 2020 Sep; 130():159-161. PubMed ID: 32624189
    [No Abstract]   [Full Text] [Related]  

  • 17. Do the Meta-Analyses Provide a Clean Bill of Health to the Use of Renin-angiotensin System Inhibitors in Coronavirus Disease 2019 (COVID-19)?
    Kow CS; Hasan SS
    Clin Infect Dis; 2021 Jul; 73(1):164-165. PubMed ID: 32770237
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical Implications of SARS-CoV-2 Interaction With Renin Angiotensin System: JACC Review Topic of the Week.
    Brojakowska A; Narula J; Shimony R; Bander J
    J Am Coll Cardiol; 2020 Jun; 75(24):3085-3095. PubMed ID: 32305401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin-II receptor blockers or angiotensin converting enzyme inhibitors for the treatment of hypertension amid COVID-19 pandemic.
    Kow CS; Hasan SS
    Expert Rev Cardiovasc Ther; 2021 Jan; 19(1):99-100. PubMed ID: 33112190
    [No Abstract]   [Full Text] [Related]  

  • 20. Therapy with RAS inhibitors during the COVID-19 pandemic.
    Spaccarotella C; Mazzitelli M; Migliarino S; Curcio A; De Rosa S; Torti C; Indolfi C
    J Cardiovasc Med (Hagerstown); 2021 May; 22(5):329-334. PubMed ID: 33795584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.